FibroBiologics has advanced its therapeutic development by commencing a Phase 1/2 clinical trial for CYWC628, a fibroblast-based treatment designed to combat diabetic foot ulcers. This initiative underscores the company's commitment to addressing chronic diseases and offers a potential breakthrough for a condition that affects a vast global population and currently lacks enduring solutions.

Detailed Report on CYWC628 Clinical Trial Launch

On Wednesday, June 3, 2026, FibroBiologics Inc. (NASDAQ: FBLG), a biopharmaceutical firm specializing in fibroblast cell-based therapies, announced the dosing of the inaugural cohort of patients in its Phase 1/2 clinical investigation of CYWC628. This investigational drug is specifically engineered to treat diabetic foot ulcers (DFUs), a widespread complication of diabetes characterized by open sores, primarily on the foot's sole. These ulcers arise from nerve damage and inadequate blood flow, impacting up to 15% of individuals with diabetes.

The clinical study is structured to involve up to 120 participants and will comprehensively evaluate the safety, tolerability, and therapeutic effectiveness of CYWC628. This innovative, topically administered allogeneic fibroblast-spheroid cell-based therapy will be benchmarked against existing standard-of-care treatments. Patients in the trial will receive either a low or high dosage of CYWC628 in conjunction with standard care, or standard care alone, over a period of up to 12 weeks. The trial is being conducted as a multicenter, randomized study across several sites in Australia, following the necessary public and private Human Research Ethics Committee (HREC) approvals.

Regular clinical and imaging evaluations will be performed to monitor wound healing progression and safety parameters. An interim analysis is scheduled to occur after participants complete six weeks of treatment, focusing on initial safety and efficacy endpoints. Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, emphasized the trial's importance, stating, "This trial offers a significant chance to demonstrate the capabilities of fibroblast-spheroid-based therapies for some of the most challenging chronic wounds." He further noted that the generated data would be crucial for understanding the broader applicability of fibroblast-spheroid cell therapy across various chronic disease indications.

In prior developments, FibroBiologics indicated in May that preliminary findings from the CYWC628 study are anticipated in the third quarter of 2026, with full safety and efficacy outcomes expected by the close of 2026. Financially, the company successfully secured $3 million in April through a public offering, issuing 2.27 million shares and warrants to acquire an equal number of shares at a combined price of $1.32. As of Tuesday's market close, FibroBiologics shares traded at $1.05, close to its 52-week low of $0.95.

The initiation of this clinical trial represents a pivotal moment for individuals suffering from diabetic foot ulcers. The current lack of consistently effective long-term solutions highlights the urgent need for new therapies. FibroBiologics' approach, utilizing fibroblast-spheroid cell-based therapy, offers a promising avenue for improved wound healing and overall patient well-being. This development not only signifies a potential advancement in DFU treatment but also underscores the growing importance of cellular therapies in addressing complex chronic conditions. The outcomes of this trial will be closely watched by the medical community and patient advocacy groups alike, as they could pave the way for a new standard of care.